Skip to main content

Advertisement

SpringerLink
Log in

Heat shock proteins as targets in oncology

  • Educational Series
  • Molecular Targets in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Heat shock proteins are ubiquitous molecular chaperones involved in posttranslational folding, stability, activation and maturation of many proteins that are essential mediators of signal transduction and cell cycle progression. Hsp90 proteins are the best studied proteins of this family. A growing number of Hsp90 client proteins have been shown to be important for the development, proliferation and survival of several types of cancer. Inhibition of Hsp90 leads to the degradation of known oncogene products, such as Her2, BRAF and others, leading to the simultaneous blockade of multiple oncogenic transduction pathways. Hsp90 inhibitors, derived from the natural compound geldanamycin, are attractive targets for anticancer drug development. We will review the clinical data on Hsp90 inhibitors in different malignancies. The best known of them, 17-AAG, has shown significant antitumour activity against a broad variety of cancers in preclinical studies, including breast, myeloma, melanoma, prostate and lung cancers. Hsp90 inhibitors can be used as single agents or in combination with other targeted treatments or chemotherapy and radiotherapy. The results of clinical phase II and III trials evaluating the efficacy of these drugs in different types of tumours are awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Welch WJ, Feramisco JR (1982) Purification of the major mammalian heat shock proteins. J Biol Chem 257:14949–14959

    CAS  PubMed  Google Scholar 

  2. Hendrick JP, Hartl FU (1993) Molecular chaperone functions of heat-shock proteins. Annu Rev Biochem 62:349–384

    Article  CAS  PubMed  Google Scholar 

  3. Felts SJ, Owen BA, Nguyen P et al (2000) The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275:3305–3312

    Article  CAS  PubMed  Google Scholar 

  4. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancers: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103

    Article  CAS  PubMed  Google Scholar 

  5. Neckers L (2002) HSP90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8: S55–S61

    Article  CAS  PubMed  Google Scholar 

  6. Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331–341

    Article  CAS  PubMed  Google Scholar 

  7. Kitano H (2003) Cancer robustness: tumour tactics. Nature 426:125

    Article  CAS  PubMed  Google Scholar 

  8. Workman P (2003) Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures? Curr Opin Investig Drugs 4:1410–1415

    CAS  PubMed  Google Scholar 

  9. Ritossa F (1962) A new puffing pattern induced by temperature and DNP in Drosophila. Experimentia 18:571–573

    Article  CAS  Google Scholar 

  10. Hartl FU, Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852–1858

    Article  CAS  PubMed  Google Scholar 

  11. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772

    Article  CAS  PubMed  Google Scholar 

  12. http://www.picard.ch/downloads/Hsp90interactors.pdf

  13. Connell P, Ballinger CA, Jiang J et al (2001) The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3:93–96

    Article  CAS  PubMed  Google Scholar 

  14. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  15. Workman P (2004) Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206:149–157

    Article  CAS  PubMed  Google Scholar 

  16. Queitsch C, Sangster TA, Lindquist S (2002) Hsp90 as a capacitor of phenotypic variation. Nature 417:618–624

    Article  CAS  PubMed  Google Scholar 

  17. Felts SJ, Owen BA, Nguyen P et al (2000) The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275:3305–3312

    Article  CAS  PubMed  Google Scholar 

  18. Grammatikakis N, Vultur A, Ramana CV et al (2002) The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 277:8312–8320

    Article  CAS  PubMed  Google Scholar 

  19. Prodromou C, Roe SM, O’Brien R et al (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65–75

    Article  CAS  PubMed  Google Scholar 

  20. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410:439–453

    Article  CAS  PubMed  Google Scholar 

  21. Connell P, Ballinger CA, Jiang J et al (2001) The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3:93–96

    Article  CAS  PubMed  Google Scholar 

  22. Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95:323–348

    Article  CAS  PubMed  Google Scholar 

  23. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419–424

    Article  CAS  PubMed  Google Scholar 

  24. Bonvini P, Gastaldi T, Falini B, Rosolen A (2002) Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 62:1559–1566

    CAS  PubMed  Google Scholar 

  25. Banerji U, O’Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161

    Article  CAS  PubMed  Google Scholar 

  26. Eustace BK, Jay DG (2004) Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 3:1098–1100

    CAS  PubMed  Google Scholar 

  27. Shimamura T, Lowell AM, Engelman JA, Shapiro GI (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65:6401–6408

    Article  CAS  PubMed  Google Scholar 

  28. Pennacchietti S, Michieli P, Galluzzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361

    Article  PubMed  Google Scholar 

  29. Georget V, Terouanne B, Nicolas J-C, Sultan C (2002) Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824–11831

    Article  CAS  PubMed  Google Scholar 

  30. Hur E, Kim HH, Choi SM et al (2002) Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 62:975–982

    Article  CAS  PubMed  Google Scholar 

  31. Zagzag D, Nomura M, Friedlander DR et al (2003) Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196:394–402

    Article  CAS  PubMed  Google Scholar 

  32. Modi S, Stopeck AT, Gordon MS et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25:5410–5417

    Article  CAS  PubMed  Google Scholar 

  33. Jhawer M, Goel S, Wilson AJ et al (2008) PIK3-CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68:1953–1961

    Article  CAS  PubMed  Google Scholar 

  34. Kelland LR, Sharp SY, Rogers PM et al (1999) DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940–1949

    Article  CAS  PubMed  Google Scholar 

  35. Machida H, Matsumoto Y, Shirai M, Kubota N (2003) Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 79:973–980

    Article  CAS  PubMed  Google Scholar 

  36. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442–447

    CAS  Google Scholar 

  37. Egorin MJ, Lagattuta TF, Hamburger DR et al (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7–19

    Article  CAS  PubMed  Google Scholar 

  38. Chandarlapaty S, Sawai A, Ye Q et al (2008) SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240–248

    Article  CAS  PubMed  Google Scholar 

  39. Roe SM, Prodromou C, O’Brien R et al (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the anti-tumor antibiotics radicicol and geldanamycin. J Med Chem 42:260–266

    Article  CAS  PubMed  Google Scholar 

  40. An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355–360

    CAS  PubMed  Google Scholar 

  41. Kamal A, Thao L, Sensintaffar J et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410

    Article  CAS  PubMed  Google Scholar 

  42. Tsutsumi S, Scroggins B, Koga F et al (2008) A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27:2478–2487

    Article  CAS  PubMed  Google Scholar 

  43. Taldone T, Gozman A, Maharaj R, Chiosis G (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8:370–374

    Article  CAS  PubMed  Google Scholar 

  44. Zhang T, Hamza A, Cao X et al (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7:162–170

    Article  CAS  PubMed  Google Scholar 

  45. Ramanathan RK, Egorin MJ, Eiseman JL et al (2007) Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13:1769–1774

    Article  CAS  PubMed  Google Scholar 

  46. Grem JL, Morrison G, Guo XD et al (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885–1893

    Article  CAS  PubMed  Google Scholar 

  47. Pacey S, Wilson R, Walton M et al (2007) A phase I of the heat shock protein 90 (HSP90) inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, alvespimycin) administered weekly [abstract 3568]. Proc Annu Meet Am Soc Clin Oncol 25:154

    Google Scholar 

  48. Elfiky A, Saif W, Beeram M et al (2008) BIIB021, an oral synthetic non ansamycin Hsp90 inhibitor: phase I experience. Proc Am Soc Clin Oncol 26:2503

    Google Scholar 

  49. Haluska P, Toft D, Steinmetz S et al (2004) A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamcyin (17-AAG) and cisplatin (CDDP) in solid tumor patients [abstract 3058]. Proc Annu Meet Am Soc Clin Oncol 23:209

    Google Scholar 

  50. Banerji U, O’Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161

    Article  CAS  PubMed  Google Scholar 

  51. Wagner A, Morgan J, Chugh R et al (2008) Inhibition of heat shock protein 90 (Hsp90) with a novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from a phase I trial [abstract 10503]. Proc Annu Meet Am Soc Clin Oncol 26:55

    Google Scholar 

  52. Modi S, Stopeck AT, Gordon MS et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25:5410–5417

    Article  CAS  PubMed  Google Scholar 

  53. Solit DB, Osman I, Polsky D et al (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14:8302–8307

    Article  CAS  PubMed  Google Scholar 

  54. Heath EI, Gaskins M, Pitot HC et al (2005) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4:138–141

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Universitario La Fe, Valencia, Spain

    Alejandra Giménez Ortiz

  2. Jefe de Servicio Oncología Médica, Hospital Universitario La Fe, Avda. Campanar, 21, ES-46009, Valencia, Spain

    Joaquín Montalar Salcedo

Authors
  1. Alejandra Giménez Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joaquín Montalar Salcedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joaquín Montalar Salcedo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giménez Ortiz, A., Montalar Salcedo, J. Heat shock proteins as targets in oncology. Clin Transl Oncol 12, 166–173 (2010). https://doi.org/10.1007/s12094-010-0486-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-010-0486-8

Keywords

Search

Navigation